Avelumab clinical trials
Also written Bavencio and MSB0010718C.
How each study uses avelumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the avelumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 23 Mar 2017 · BAVENCIO · BLA 761049 (FDA, Drugs@FDA)
- European Union
- 18 Sept 2017 · Bavencio · EMEA/H/C/004338 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
161 studies that test it; most in 2018 (43)
| Year | Studies |
|---|---|
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 7 |
| 2016 | 11 |
| 2017 | 38 |
| 2018 | 43 |
| 2019 | 22 |
| 2020 | 13 |
| 2021 | 7 |
| 2022 | 8 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 4 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 34 · Other 127
Pfizer (16) · EMD Serono Research & Development Institute, Inc. (11) · National Cancer Institute (NCI) (5) · Gruppo Oncologico del Nord-Ovest (5) · M.D. Anderson Cancer Center (4) · Memorial Sloan Kettering Cancer Center (4) · Dana-Farber Cancer Institute (3) · Merck KGaA, Darmstadt, Germany (3)
Often tested with
Tested in the same studies.
Axitinib (13) · Cetuximab (8) · Palbociclib (6) · Talazoparib (5) · Gemcitabine (5) · Paclitaxel (4) · Peposertib (3) · Nivolumab (3)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 13, 2 in phase 3
Studies that test avelumab, phase 3 first.
- Nov 2026Avelumab Program Rollover StudyPhase 3 · EMD Serono Research & Development Institute, Inc.
- Dec 2026Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are ClosingPhase 3 · Pfizer
- Nov 2026Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell CarcinomaPhase 2 · Melanoma and Skin Cancer Trials Limited
- Dec 2026A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based ChemotherapyPhase 2 · University Health Network, Toronto
- Jan 2027Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial CancerPhase 2 · M.D. Anderson Cancer Center
- Mar 2027Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell CarcinomaPhase 2 · Memorial Sloan Kettering Cancer Center
- Mar 2027A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based ChemotherapyPhase 2 · National Cancer Institute (NCI)
- Apr 2027TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast CancerPhase 1/2 · Georgetown University
- Apr 2027Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal TherapyPhase 1/2 · National Cancer Institute (NCI)
- Jun 2027Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial CancerPhase 2 · Queen Mary University of London
Studies
Open first, then newest update. How each study uses avelumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 161
- DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile CarcinomaRecruitingPhase 2Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestNCT07110038Written as Avelumab
- European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsRecruitingPhase 1/2Gustave Roussy, Cancer Campus, Grand ParisNCT02813135Written as Avelumab
- Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial CancerRecruitingPhase 2Queen Mary University of LondonNCT06892860Written as Avelumab
- Maintenance AVElumab After SECond Line Platinum-based Chemotherapy for Metastatic Urothelial CarcinomaNot yet recruitingPhase 2Gruppo Oncologico Italiano di Ricerca ClinicaNCT07460245Written as Avelumab 800 mg flat-dose IV
- Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUCRecruitingPhase 2Samsung Medical CenterNCT07225374Written as Avelumab 10 mg/kg
- TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial CarcinomaRecruitingPhase 2Centre Francois BaclesseNCT04678362Written as Talazoparib + Avelumab
- ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic ProfilingRecruitingPhase 2Ulrik LassenNCT04341181Written as Avelumab
- Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.RecruitingPhase 2Gruppo Oncologico del Nord-OvestNCT06869473Written as Cetuximab/avelumab
- Avelumab and Methotrexate in in Low-risk Gestational Trophoblastic Neoplasias as First Line TreatmentRecruitingPhase 1/2Hospices Civils de LyonNCT04396223Written as Avelumab Injection
- CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge StrategyRecruitingPhase 2University of Campania Luigi VanvitelliNCT05291156Written as Avelumab
- Chemotherapy and Sequential Immunotherapy for Locally Advanced Urothelial CancerRecruitingPhase 2Erasmus Medical CenterNCT05600127Written as Avelumab
- A Phase I/II Study of Regorafenib Plus Avelumab in Solid TumorsRecruitingPhase 1/2Institut BergoniéNCT03475953Written as Phase 1 : Avelumab
- Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal TherapyActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT04071236Written as Avelumab
- Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile CarcinomaCompletedPhase 2Centre Hospitalier Universitaire de BesanconNCT03774901Written as Avelumab
- Avelumab With Valproic Acid in Virus-associated CancerCompletedPhase 2AHS Cancer Control AlbertaNCT03357757Written as Avelumab
- A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based ChemotherapyActive, not recruitingPhase 2National Cancer Institute (NCI)NCT03076554Written as Avelumab
- Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP StudyCompletedEarly Phase 1Austin HealthNCT03244176Written as Avelumab
- Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are ClosingActive, not recruitingPhase 3PfizerNCT05059522Written as Avelumab
- Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast CancerActive, not recruitingPhase 2Abramson Cancer Center at Penn MedicineNCT04841148Written as Avelumab
- Immunotherapy in Combination With Chemotherapy in Small-cell Lung CancerCompletedPhase 2Hellenic Cooperative Oncology GroupNCT03568097Written as Avelumab
See all 161 studies that test avelumab →
Given beside what is tested · 83 — avelumab is usual care or a partner of the new treatment
- Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)RecruitingPhase 2National Cancer Institute (NCI)NCT06228066Written as Avelumab
- Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI TrialRecruitingPhase 2NRG OncologyNCT05327686Written as Avelumab
- Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic CancerRecruitingPhase 1/2Aulos Bioscience, Inc.NCT05267626Written as Avelumab
- Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell CarcinomaRecruitingPhase 1/2Kartos Therapeutics, Inc.NCT03787602Written as Avelumab
- Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary MalignanciesActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT04068194Written as Avelumab
- Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV StudyActive, not recruitingPhase 3National Cancer Institute (NCI)NCT05092958Written as Avelumab
- Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid TumorsActive, not recruitingPhase 1/2M.D. Anderson Cancer CenterNCT04266912Written as Avelumab
- Avelumab and M1774 in ARID1A-mutated Endometrial CancerActive, not recruitingPhase 2Panagiotis Konstantinopoulos, MD, PhDNCT06518564Written as Avelumab
- Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced MalignanciesActive, not recruitingPhase 1/2M.D. Anderson Cancer CenterNCT03217747Written as Avelumab
- Trial of INI-4001 in Patients With Advanced Solid TumoursCompletedPhase 1Inimmune CorporationNCT06302426Written as Avelumab
- Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1Active, not recruitingPhase 1TILT Biotherapeutics Ltd.NCT05222932Written as Avelumab
- Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell LymphomaCompletedPhase 1City of Hope Medical CenterNCT03440567Written as Avelumab
- Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast CancerActive, not recruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT03573648Written as Avelumab
- Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin MalignancyActive, not recruitingPhase 1University of Southern CaliforniaNCT04387084Written as Avelumab
- Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)CompletedPhase 1EMD Serono Research & Development Institute, Inc.NCT05396833Written as Avelumab
- Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX TrialActive, not recruitingPhase 2National Cancer Institute (NCI)NCT05947500Written as Avelumab
- Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS TumorsTerminatedPhase 1EMD Serono Research & Development Institute, Inc.NCT05081180Written as Avelumab
- The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast CancerActive, not recruitingPhase 2Adrienne G. WaksNCT03414658Written as Avelumab
- A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic CancersActive, not recruitingPhase 1iOncturaNCT04328844Written as Avelumab Injection
- Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell CancerActive, not recruitingPhase 2Alliance for Clinical Trials in OncologyNCT03944941Written as Avelumab
Showing 20 of 83.
As the comparator · 3 — what is tested is compared with avelumab
- Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)Active, not recruitingPhase 2BicycleTx LimitedNCT06225596Written as Avelumab
- Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has SpreadActive, not recruitingPhase 2Gilead SciencesNCT03547973Written as Avelumab
- Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)CompletedPhase 3EMD Serono Research & Development Institute, Inc.NCT02625623Written as Avelumab
Codes
What other systems call avelumab · ClinicalTrials.gg INT000497
- MeSH (NLM) C000609138avelumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) KXG2PJ551IAVELUMABConfirmed FDA, NLM, Wikidata
- RxNorm 1875534Confirmed FDA, Wikidata
- Wikidata Q21083261avelumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C116870AvelumabOne source FDA
- DrugBank DB11945One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000609138 | avelumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | KXG2PJ551I | AVELUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1875534 | — | Confirmed FDA, Wikidata |
| Wikidata | Q21083261 | avelumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C116870 | Avelumab | One source FDA |
| DrugBank | DB11945 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.